Biomarkers Market Share, Trends, Opportunities and Growth Forecast To 2030

Biomarkers Market Size, Share & Trends Analysis By Product, By Type, By Application, By disease indication, By Regional Outlook, Competitive Strategies and Segment Forecast to 2030

Biomarkers Market Size, Share & Trends Analysis By Product, By Type, By Application, By disease indication, By Regional Outlook, Competitive Strategies and Segment Forecast to 2030

Published: Mar 2022 Report ID: BIOT2211 Pages: 1 - 251 Formats*:     
Category : Biotechnology
Global Biomarkers Market Overview:

According to SPER Market Research, the Biomarkers Market is estimated to reach USD 117.6 billion by 2030 with a CAGR of 11.8%. Companion diagnostics, growing incidence of cancer globally, escalating funds & grants for biomarker research, and persistent innovations; these are the key factors acting as the fuel for the expansion of this market.

Impact of COVID-19 on the Biomarkers Market
Biomarkers play a vital role in the diagnosis of COVID-19. Patients with rigorous complications of COVID-19 have higher biomarkers level like cardiac troponin, renal biomarkers, lymphocytes, platelet count, C-reactive protein, serum amyloid A, and interleukin-6. Lymphocytes and platelet count is considerably lower in severe patients. To sustain COVID-19 research, the top players of this market developed assay and test kits. COVID-19 has a positive impact on this market expansion.

Scope of the report:
 Report Metric Details
 Market size available for years 2019-2030
 Base year considered 2021
 Forecast period 2022-2030
 Segments coveredBy Product, By Type, By Application, By Disease Indication, By Region
 Geographies covered North America, Europe, Asia Pacific, Latin America , Middle East, Africa
 Companies CoveredAbbott Laboratories, Bio-Rad Laboratories, Inc., Charles River Laboratories, International, Inc., Enzo Biochem, Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd., Merck KGaA, PerkinElmer, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc. 

Driver: increasing significance of companion diagnostics
Biomarkers, with the capability to spot drug target molecules play an important function in the development of companion diagnostics. Biomarkers & Companion diagnostics are important in the practice of medicine; this allows superior diagnosis, cure, and monitor numerous disease. These diagnostics are frequently used to identify patients apt to react well to certain drugs or treatment options, also used in combination with a specific drug. Accordingly, increase in the significance of companion diagnostics lead to escalation of this market.

Restraint: More capital investments and extended periods for biomarker development
The validation of the biomarkers development is a more time taking procedure, and costly. 

Challenges: biomarker validation
Biomarkers validation is an expensive method, sensitive, inaccurate.

Opportunity: Personalized medicine
Biomarkers have a major role in the personalized medicine and companion diagnostics.
Due to demand for personalized medicine globally; offers enormous opportunities in this field.  

Global Biomarkers Market Segmentation:

By Product: Based on the Product, Biomarkers market is segmented as; Consumables, Services, Software.

By Type: Based on the Type, Biomarkers market is segmented as;Efficacy Biomarkers, Pharmacodynamics Biomarkers, Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, Surrogate Biomarkers, Validation Biomarkers.

By Application: Based on the Application, Biomarkers market is segmented as; Diagnostics, Disease Risk Assessment, Drug Discovery & Development, Other Applications, Personalized Medicine.

By Disease Indication: Based on the Disease Indication, Biomarkers market is segmented as; Cancer by Test Type (Solid biopsy, Liquid Biopsy), Infectious Diseases, Immune Disorders, Neurological Disorders, Cardiovascular Disorders, Other Disease Indications.

By Region: North America owns the prime share of this market; it is due to the implementation of biomarkers in the diagnosis of diseases like cancer diagnosis, rising exploitation of biomarkers in personalized medicine, presence of big pharmaceutical companies, and adoption of strategies for the escalation of the market. 

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. COVID-19 Impact on the Biomarkers Market
4.4. Market Trends

5. Global Biomarkers Market, by Product, 2019-2030 (USD Million)
5.1. Consumables
5.2. Services
5.3. Software

6. Global Biomarkers Market, by Type, 2019-2030 (USD Million)
6.1. Efficacy Biomarkers
6.2. Pharmacodynamics Biomarkers
6.3. Predictive Biomarkers
6.4. Prognostic Biomarkers
6.5. Safety Biomarkers
6.6. Surrogate Biomarkers
6.7. Validation Biomarkers

7. Global Biomarkers Market, by Application, 2019-2030 (USD Million)
7.1. Diagnostics
7.2. Disease Risk Assessment
7.3. Drug Discovery & Development
7.4. Other Applications
7.5. Personalized Medicine

8. Global Biomarkers Market, by Disease Indication, 2019-2030 (USD Million)
8.1. Cancer by Test Type
8.1.1. Solid biopsy
8.1.2. Liquid Biopsy
8.2. Infectious Diseases
8.3. Immune Disorders
8.4. Neurological Disorders
8.5. Cardiovascular Disorders
8.6. Other Disease Indications

9. Global Biomarkers Market, by Region, 2019-2030 (USD Million)
9.1. North America
9.1.1. US
9.1.2. Canada
9.2. Europe
9.2.1. France 
9.2.2. Germany 
9.2.3. Italy 
9.2.4. Spain 
9.2.5. Rest of the Europe
9.3. Asia Pacific 
9.3.1. China
9.3.2. India 
9.3.3. Japan
9.3.4. Rest of Asia Pacific
9.4. Latin America
9.5. Middle East 
9.6. Africa

10. Competitive Landscape
10.1. Introduction
10.2. Market Share Analysis, By Key Players 
10.3. Competitive Scenario 
10.3.1. Product Launches
10.3.2. Partnerships, Collaborations and Agreements
10.3.3. Acquisitions
10.3.4. Expansions
10.3.5. Other Developments

11. Company Profiles
11.1. Abbott Laboratories 
11.2. Bio-Rad Laboratories, Inc. 
11.3. Charles River Laboratories International, Inc. 
11.4. Enzo Biochem, Inc.
11.5. Eurofins Scientific 
11.6. F. Hoffmann-La Roche Ltd.
11.7. Merck KGaA
11.8. PerkinElmer, Inc.
11.9. QIAGEN N.V.
11.10. Thermo Fisher Scientific Inc. 

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.




Not able to find what you are looking for? Need customization in the existing report?
Click Here
  • 15% off
    $ 4250
  • 20% off
    $ 5650
  • 25% off
    $ 7450
Pre-Purchase Inquiry
Request Customization
100% Secure Payment

SPER American Express
SPER Master Card
SPER Mestro
SPER Paypal
SPER CCAvenues

Join Our SPER Panel

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Johnson & Johnson
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Johnson & Johnson


Market Research

We are the leading, full-service global market research and consulting company.

iso-1 iso-1
Secure Payments
SPER Payment Options
Connect with us